NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

Jazz Pharmaceuticals logo
$230.40 -6.05 (-2.56%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$230.66 +0.25 (+0.11%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Advanced

Key Stats

Today's Range
$227.95
▼
$238.59
50-Day Range
$205.06
▼
$248.24
52-Week Range
$156.95
▼
$266.38
Volume
984,645 shs
Average Volume
794,665 shs
Market Capitalization
$14.79 billion
P/E Ratio
78.37
Dividend Yield
N/A
Price Target
$294.25
Consensus Rating
Moderate Buy

Company Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines. Bruce Cozadd, a company co-founder, serves as chairman and chief executive officer.

AI Generated. May Contain Errors.

Jazz Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

JAZZ MarketRank™: 
4.365697593545 of 5 stars

Jazz Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 28th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 1 strong buy rating, 17 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Jazz Pharmaceuticals has a consensus price target of $294.25, representing about 27.7% upside from its current price of $230.40.

  • Amount of Analyst Coverage

    Jazz Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Jazz Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Jazz Pharmaceuticals are expected to grow by 114.94% in the coming year, from $11.18 to $24.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Jazz Pharmaceuticals is 78.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.55.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Jazz Pharmaceuticals is 78.37, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.93.

  • Price to Earnings Growth Ratio

    Jazz Pharmaceuticals has a PEG Ratio of 0.43. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Jazz Pharmaceuticals has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.42% of the float of Jazz Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.67.
  • Change versus previous month

    Short interest in Jazz Pharmaceuticals has recently decreased by 1.12%, indicating that investor sentiment is improving.
  • Dividend Yield

    Jazz Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Jazz Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Jazz Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Jazz Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    23 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,420,491.00 in company stock.

  • Percentage Held by Insiders

    4.10% of the stock of Jazz Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Jazz Pharmaceuticals' insider trading history.
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JAZZ Stock News Headlines

Should You Buy Jazz Pharmaceuticals Stock For Its Cash?
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Needham
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Jazz Pharmaceuticals Earnings Call Signals Broad Growth Momentum
See More Headlines

JAZZ Stock Analysis - Frequently Asked Questions

Jazz Pharmaceuticals' stock was trading at $170.00 at the beginning of the year. Since then, JAZZ shares have increased by 35.5% and is now trading at $230.4040.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating analysts' consensus estimates of ($4.03) by $0.15. The firm's revenue was up 10.4% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion.

Jazz Pharmaceuticals' top institutional investors include State Street Corp (3.22%), American Century Companies Inc. (0.88%), William Blair Investment Management LLC (0.67%) and Boston Trust Walden Corp (0.65%). Insiders that own company stock include Bruce C Cozadd, Renee D Gala, Seamus Mulligan, Robert Iannone, Neena M Patil, Mary Elizabeth Henderson, Philip L Johnson, Heather Ann Mcsharry, Mark Douglas Smith, Rick E Winningham, Norbert G Riedel and Patricia Carr.
View institutional ownership trends
.

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/02/2026
Today
11/21/2026
38th Annual Healthcare Conference
12/02/2026
Citi Annual Global Healthcare Conference 2026
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:JAZZ
CIK
1232524
Employees
2,890
Year Founded
2003

Price Target and Rating

High Price Target
$337.00
Low Price Target
$220.00
Potential Upside/Downside
+27.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.95
Research Coverage
20 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.94
Trailing P/E Ratio
78.37
Forward P/E Ratio
9.59
P/E Growth
0.43
Net Income
-$356.15 million
Net Margins
4.37%
Pretax Margin
5.51%
Return on Equity
16.88%
Return on Assets
6.46%

Debt

Debt-to-Equity Ratio
1.09
Current Ratio
1.82
Quick Ratio
1.64

Sales & Book Value

Annual Sales
$4.27 billion
Price / Sales
3.47
Cash Flow
$15.63 per share
Price / Cash Flow
14.74
Book Value
$65.30 per share
Price / Book
3.53

Miscellaneous

Outstanding Shares
64,190,000
Free Float
61,557,000
Market Cap
$14.79 billion
Optionable
Optionable
Beta
0.38

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:JAZZ) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners